brain — overview

Due today

Today's calendar — Saturday, 6 June 2026

Deadlines

Open decisions / ?c? markers across the brain

Proposed for next Fri 14:00: "Scope the strategy queue itself" — Eike said more than the four originally listed topics need sorting; first Fri post-launch is the right place.k

Queue

1. **Think about full Imaging Project**: understand milestones and timeframes, plan Gantt properly, move plan into todos and action points, delegate specific areas - 2 hours
2. **VP WP1/WP2 ownership lock** — 1 h after planning Imaging Project
3. **Cooperations strategy** — several partners, think about overall picture, then each possible cooperation: Bender/Loewe IBT, Heidelberg (CMR group, clinical), Messina, Berlin (Kelle), HZ Bad Bevensen, Berlin (AI group), Heidelberg (AI group)
4. **CMR-AI product roadmap** — Goethe CVI side
5. **Grants strategy** — longlist sequencing + DFG HFpEF Methods rewrite
6. **Bad Orb**
7. **long term strategy for longivity**
8. **branding**
9. **trAIectories:** new company?
10. **Goethe CVI:** how to finalize the contours?
11. **DZHK Professorenkonferenz — speaker role** (Eike, 2026-06-04): Eike is **now speaker of the DZHK professors**. Strategic question: how to make a real impact in this role? What's the agenda — research-political reform, member-side advocacy, scientific direction, structural reform of DZHK governance? What does "speaker of DZHK professors" actually have leverage over (Vorstand seat? agenda-setting power? formal/informal influence)? Who are the other professors and what do they collectively want? First-pass scoping at a future Friday strategic block.
12. **MR vendor strategy** — the bigger frame Canon sits inside. Goal: get a real alternative / second source away from the major vendors. Decision lens: field strength, cost, CMR capability, openness to external tools (own feedback loop + AI-supported scanning with no human in the loop), current vendor partners. See **§ MR vendor landscape** below for the assessment table. (Added 2026-06-03 from talkback "todo: canon re MR scanner" + Eike's 2026-06-03 reframing.)
13. **Locate the prior "available databases + access + gaps" search** — Eike recalls a systematic search of databases (which ones, how to get access, where they have holes). **Not found in the brain after a 2026-06-03 search** — closest is the CPI Hub 3 "available databases" table (no access/gaps columns) + the DZHK HFpEF cluster-notes gap-analysis (project-level, not database-level). Likely lives in Eike's local files, Dropbox grants folder, or email. Find it → add to brain at `40-infrastructure/database-landscape/` so it's queryable next time.
14. **SpinLab hyperpolarizer feasibility on FFM Prisma** (from `@strategy` marker 2026-06-03) — three sub-questions: (a) **Can it run on the current Prisma 3T?** Short answer: yes, with a kit. Prisma needs the **Siemens multinuclear / X-nucleus broadband channel option** + a **¹³C/¹H dual-tuned chest coil** (Rapid Biomedical or vendor) + **13C-aware sequences** (spiral CSI, IDEAL spiral — research/clinical pulse-program work). SPINlab is installed adjacent to the scanner room (≤20 m, ideally <10 m for the transport corridor) per documented installations at WashU, UMaryland, etc. *Open: confirm with Siemens Erlangen whether FFM's specific Prisma serial has the X-nucleus channel installed or is upgradeable.* (b) **What's needed in the future?** A SPINlab unit itself (capital ~€1.5–2.5 M; service contract ~€100-150k/yr; sterile single-use Fluid Path cartridges ~€500–1k each); compounding room compliant with EU GMP / USP 797 (sterile preparation suite); IND/IMP regulatory dossier for clinical use; trained staff (chemist + radiographer + pharmacist for release; see (c)). (c) **Do I still need a pharmacologist?** **Mostly yes, still, but the per-scan workload is small.** SPINlab's built-in QC module auto-measures pyruvate concentration, residual radical (OX063), pH, polarization, temperature, volume — handles the **chemical release decision** automatically. However, the EU Arzneimittelgesetz still classifies the hyperpolarized pyruvate solution as an **investigational medicinal product (IMP)** for human use, which requires a **qualified person (QP) / pharmacist** to authorise release (regulatory rather than chemical-QC). In **animal/research use** the QP requirement falls away. The Würzburg / Oxford / Cambridge translational HP-¹³C centres all operate with a (low-burden) pharmacist-in-the-loop model. Worth a call to GE Healthcare clinical scientific affairs + an EU-side site like Aarhus DK or Cambridge UK for the practical Germany answer. *Park as a real evaluation if the Würzburg discussion (22 Jun) suggests this is the right direction for FFM.* (Added 2026-06-03 via `@strategy` marker.)
15. _(+ unenumerated — enumerate at next Fri session)_

Add to queue by editing _morning/STRATEGY.md directly, or by dropping @strategy <topic> into any STATE.md — tomorrow's sweep will move it here.

For things not in any list above. Type freely, pick a prefix, send. Autosaves between sessions.